Estrella Immunopharma Inc. (ESLA : NASDAQ)
Common Stock
$0.54
USD
+0.22 (68.35%)
Last updated: 2026-10-15
Follow ESLA
ESLA
Estrella Immunopharma Inc.
WealthAwesomePerformance
1 Day
+68.35%
1 Week
+28.19%
1 Month
-12.41%
YTD
-47.01%
Key Statistics
Market Cap
$23.28M
52W High
$3.15
52W Low
$0.29
P/E Ratio
-
50 Day MA
$0.60
200 Day MA
$1.03
Beta
0.93
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/15/2026 | $0.31 | $0.85 | $0.30 | $0.54 | $0.54 | 59,698,205 |
| 10/14/2026 | $0.31 | $0.33 | $0.30 | $0.32 | $0.32 | 182,666 |
| 10/13/2026 | $0.33 | $0.34 | $0.29 | $0.31 | $0.31 | 314,187 |
| 10/12/2026 | $0.33 | $0.36 | $0.32 | $0.33 | $0.33 | 882,214 |
| 10/9/2026 | $0.35 | $0.44 | $0.31 | $0.41 | $0.41 | 19,789,300 |
| 10/8/2026 | $0.41 | $0.43 | $0.36 | $0.42 | $0.42 | 71,096 |
| 10/7/2026 | $0.41 | $0.44 | $0.41 | $0.42 | $0.42 | 48,893 |
| 10/6/2026 | $0.44 | $0.46 | $0.41 | $0.43 | $0.43 | 68,650 |
| 10/5/2026 | $0.46 | $0.46 | $0.44 | $0.44 | $0.44 | 31,136 |
| 10/2/2026 | $0.46 | $0.51 | $0.46 | $0.47 | $0.47 | 14,500 |
Analyst Price Targets
Based on analyst covering ESLA · as of Oct 5, 2026
Wall Street analysts forecast ESLA stock price to rise 2142.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
US$12.00
+2142.2% Upside
Current Price
US$0.54
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ESLA's historical volatility
30-Day Vol
186.4%
Annualized
90-Day Vol
122.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$0.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$0.50 | US$0.27 – US$0.96 |
| 60 trading days | US$0.48 | US$0.19 – US$1.18 |
| 90 trading days | US$0.45 | US$0.15 – US$1.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Estrella Immunopharma Inc.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- -268.50%
- EPS (Diluted)
- -0.43
- Book Value
- -0.17
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ESLA.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| KNDI | Kandi Technologies Group Inc | $4.11 | +928.50% |
| SDST | Stardust Power Inc. | $0.04 | +55.38% |
| XLAB | Exascale Labs Holdings Inc. Class A Common Stock | $1.36 | +49.70% |
| WETO | Webus International Limited Ordinary Shares | $1.22 | +46.88% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +40.85% |
| DRMA | Dermata Therapeutics Inc | $0.91 | +37.19% |
| LESLQ | Leslie's, Inc. | $0.03 | +35.75% |
| SVRE | SaverOne 2014 Ltd. American Depositary Shares | $1.65 | +35.25% |